532067

3B Blackbio share price & financials

Price
₹1,196.5
Market cap
₹1.2k Cr
Sector
Healthcare
Calls analysed
3
Latest concall · Q4 FY26 · call held 01 Jun 2026

3B Blackbio Q4 FY26

Consolidated Revenue ₹142 cr Consolidated EBITDA Margin 40% Consolidated PAT ₹60 cr

What went well

  • Strong consolidated revenue of INR142 crores and PAT of INR60 crores for FY26, reflecting healthy growth across diagnostic businesses.
  • TRUPCR Europe delivered consistent growth with a CAGR of approximately 40% over four years, reaching GBP1.75 million (INR20.67 crores) in sales for FY26.
  • Coris BioConcept, acquired in August, made a meaningful contribution with INR35.91 crores in sales and INR8.76 crores in PAT for 7 months.

What to watch

  • 3B India's molecular diagnostic business growth of 10% was slightly lower than projections due to exceptional flu/dengue demand in FY25 and geopolitical tensions impacting exports.
  • Coris BioConcept's EBITDA margin is currently low (around 10%) and is expected to be only slightly positive in FY27, with Q1 and Q2 FY27 projected to be loss-making due to seasonality.
Read the full call →

What 3B Blackbio does

3B BlackBio Dx Limited (formerly Kilpest India Limited) designs, develops and manufactures molecular diagnostic kits under the TRUPCR (qPCR), TRURAPID (lateral flow), TRUNGS (NGS) and TRUdPCR (digital PCR) brands at its Bhopal facility, selling to hospitals and diagnostic labs in India and 70+ countries through direct supply, government tenders and long-term reagent-rental contracts where it places PCR/extraction instruments and locks customers into its assays. It also runs a legacy agrochemicals business making insecticides, fungicides, herbicides, bio-pesticides and related formulations, sold mainly through government e-tenders (GeM) and exports to Bangladesh. Its UK subsidiary TRUPCR Europe Limited (Manchester) manufactures/sells a 'Made in UK' molecular diagnostics range, and Belgium-based Coris BioConcept SRL (acquired August 2025) adds rapid lateral-flow diagnostic tests, including antimicrobial-resistance (AMR) and tropical-disease (HAT) products.

Segments

  • Molecular Diagnostics (MDx) - 3B India
  • Agrochemicals
  • TRUPCR Europe Limited (Manchester, UK)
  • Coris BioConcept SRL (Belgium)
Molecular diagnostic assays developed
120+ PCR/molecular diagnostic assays
International country presence
70+ countries (Europe, Middle East, APAC, LATAM, North America)
India lab/hospital reach
1,000+ labs and hospitals across 100+ Indian cities
Global MDx customer base (incl. Coris, FY26)
1,000+
Long-term reagent-rental contracts in place
15+
Installed capacity utilization
~65% (up to full during seasonal disease outbreaks; ~50% in lean season)
Founded 1972Headquarters Bhopal, Madhya Pradesh, India Company website

Guidance record · Q4 FY26

what the last two calls moved 12 tracked 2 delivered 2 missed 8 open
  • Overall Revenue Growth delivered, diluted said Q1 FY26 Promised: 15% to 20% for FY25-26 Q4 FY26: if we include the export growth of say 25% odd, we reach a growth of consolidated growth of 10%.
  • Indian Business EBITDA Margin went quiet said Q1 FY26 Promised: Towards a 55 site rather than the 60 site Q4 FY26: No specific update provided on the 55% target for the Indian business margin.
  • Coris EBITDA Status on track said Q1 FY26 Promised: EBITDA positive in 2026-27 Q4 FY26: I would say that Coris will be EBITDA flat, number 1, we have already claimed this. That Coris will be slightly EBITDA positive.

All 12 tracked — every revision, and every one management stopped mentioning.

Open the guidance ledger

Quarterly results

Q1 FY27: revenue up 50.7%, net profit down 29.0% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue29 25 23 22 34 +16%50 +98%35 +57%33 +51%
EBITDA16 15 8 12 15 −9%22 +44%8 +7%9 −28%
Net profit15 13 8 13 15 +1%22 +66%10 +22%9 −29%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance +1.2% 1Y

₹1.2k₹1.4k₹1.6kSept 25Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Q3 FY26 — 20 Feb 2026Q4 FY26 — 1 Jun 2026

1Y: ₹1,410.35 on 10 Sept 2025 → ₹1,427.05. High ₹1,695.75 (16 Jan 2026), low ₹1,105.25 (1 Jun 2026).

How the price took the results

close before → close after

Q4 FY26
−11.2%
1 Jun
Q3 FY26
−0.9%
21 Feb

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Financials, as filed

Revenue grew 31.7% a year over 3 years, FY23 to FY26. Operating margin narrowed to 40.0%.

Year endingFY23FY24FY25FY26
Revenue₹62 Cr₹74 Cr₹96 Cr₹142 Cr
Operating profit₹28 Cr₹33 Cr₹50 Cr₹57 Cr
Operating margin45.8%44.5%51.9%40.0%
Interest₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Depreciation₹0 Cr₹1 Cr₹1 Cr₹5 Cr
Net profit₹26 Cr₹32 Cr₹48 Cr₹60 Cr
Net margin42.2%43.3%49.4%42.2%
Cash from operations₹20 Cr₹27 Cr₹43 Cr₹52 Cr
Free cash flow₹18 Cr₹26 Cr₹42 Cr₹27 Cr
ROCE19.0%21.0%26.0%25.0%
How to read this

From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.

Balance sheet

Year endingFY21FY22FY23FY24FY25FY26
Equity capital₹7 Cr₹7 Cr₹9 Cr₹9 Cr₹9 Cr₹9 Cr
Reserves₹125 Cr₹146 Cr₹185 Cr₹214 Cr₹290 Cr₹316 Cr
Borrowings₹2 Cr₹3 Cr₹2 Cr₹1 Cr₹0 Cr₹3 Cr
Other liabilities₹59 Cr₹37 Cr₹19 Cr₹24 Cr₹42 Cr₹51 Cr
Total liabilities₹194 Cr₹192 Cr₹214 Cr₹248 Cr₹341 Cr₹378 Cr
Fixed assets₹5 Cr₹7 Cr₹8 Cr₹7 Cr₹17 Cr₹28 Cr
Capital work in progress₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Investments₹59 Cr₹93 Cr₹92 Cr₹117 Cr₹160 Cr₹158 Cr
Other assets₹130 Cr₹93 Cr₹114 Cr₹123 Cr₹163 Cr₹193 Cr
Total assets₹194 Cr₹192 Cr₹214 Cr₹248 Cr₹341 Cr₹378 Cr
How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

Who owns it

As disclosed at Jun 2026

Since Jun 2025, DIIs added +0.39 pp while promoters trimmed −0.33 pp. The shareholder count grew 4% to 11,049.

Promoters
41.0%
FIIs
2.5%
DIIs
2.1%
Public
54.4%

Since Jun 2025

  • DIIs +0.39 pp
  • Promoters −0.33 pp
  • FIIs −0.20 pp

How it drifted, 12 quarters

Over this window the public fell from 57.6% to 54.4% — −3.2 pp.

Sep '23Dec '24Jun '26

Ownership split by quarter, oldest first. Sep '23: Promoters 38.4%, FIIs 3.2%, DIIs 0.8%, Public 57.6%.Dec '23: Promoters 38.4%, FIIs 3.4%, DIIs 1.2%, Public 57.0%.Mar '24: Promoters 41.3%, FIIs 3.0%, DIIs 1.9%, Public 53.9%.Jun '24: Promoters 41.3%, FIIs 3.3%, DIIs 2.0%, Public 53.5%.Sep '24: Promoters 41.3%, FIIs 3.3%, DIIs 2.0%, Public 53.5%.Dec '24: Promoters 41.3%, FIIs 2.7%, DIIs 1.7%, Public 54.3%.Mar '25: Promoters 41.3%, FIIs 2.5%, DIIs 1.6%, Public 54.6%.Jun '25: Promoters 41.3%, FIIs 2.7%, DIIs 1.8%, Public 54.3%.Sep '25: Promoters 41.3%, FIIs 2.6%, DIIs 1.8%, Public 54.3%.Dec '25: Promoters 41.3%, FIIs 2.6%, DIIs 1.9%, Public 54.3%.Mar '26: Promoters 40.9%, FIIs 2.6%, DIIs 2.0%, Public 54.5%.Jun '26: Promoters 41.0%, FIIs 2.5%, DIIs 2.1%, Public 54.4%.

Who was buying across the market this quarter →

Who bought this quarter

since Mar 2026

Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.

The same filing shows 0 holders trimming and 1 off the list — both are in the register beside this.

Who is on the register

Named in the Jun 2026 filing

Every holder of 3B Blackbio above SEBI's 1% disclosure line, and what changed since Mar 2026.

HolderStakeChange
Mithla Dubey 12.35%unchanged
Mithala Laboratories Private Limited 9.56%unchanged
Dhirendra Dubey 8.45%unchanged
Rashi Daga 5.62%+0.09 pp
Prateek Goel 5.14%unchanged
Own Infracon Private Limited 4.41%unchanged
Nikhil Kuber Dubey 4.17%unchanged
Maj Navraj Singh Grewal 2.65%unchanged
2B Blackbio S.L. Spain 2.48%unchanged
Ram Kuber Dhirendra Kumar 2.27%unchanged
Ark Global Emerging Companies, Lp FPI fund1.94%unchanged
Dalmus Performance Focused Fund AIF1.87%unchanged

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

What the price assumes

Attractive

To justify its price of ₹1427, this stock must grow earnings at 20% every year for 7 years. Our analysis caps realistic growth at ~27%. At that growth it is worth ₹2055 — upside of 44%.

Growth the price implies
19.9% a year
for 7 years, fading to 4%
It has actually compounded at
31.8% a year
net profit, FY23–FY26 · EPS 27.1%
The gap
-0.1 pp
44% downside if it only repeats history
Price today ₹1,427.05 Value at the reference growth ₹2,054.89

Change the assumptions yourself →

All earnings calls (3)

Read the Q4 FY26 call →

Learn to analyse 3B Blackbio

Guides on how to read this kind of business and the numbers that matter.